betoptic-s single dose augentropfensuspension
medius ag - betaxololum - augentropfensuspension - betaxololum 2.5 mg ut betaxololi hydrochloridum, natrii polystyrensulfonas, carbomerum 974p, mannitolum, acidum hydrochloridum aut natrii hydroxidum, aqua, ad suspensionem pro 1 ml. - le glaucome - synthetika
betoptic suspension single dose 2,5 mg/ml collyre susp. flac. compte-gouttes
novartis pharma sa-nv - chlorhydrate de bétaxolol 2,8 mg/ml - eq. bétaxolol 2,5 mg/ml - collyre en suspension - 2,5 mg/ml - chlorhydrate de bétaxolol 2.8 mg/ml - betaxolol
single-shot epidural anesthesia tray liquide
baxter corporation - chlorhydrate de lidocaïne; chlorure de sodium - liquide - 1%; .9% - chlorhydrate de lidocaïne 1%; chlorure de sodium .9% - local anesthetics
cisatracurium besylate injection single dose solution
fresenius kabi canada ltd - cisatracurium (bésilate de cisatracurium) - solution - 2mg - cisatracurium (bésilate de cisatracurium) 2mg - neuromuscular blocking agents
panacur granule singles poudre
intervet canada corp - fenbendazole - poudre - 222mg - fenbendazole 222mg - chiens
polysporin singles pommade
johnson & johnson inc - sulfate de polymyxine b; bacitracine de zinc - pommade - 10000unité; 500unité - sulfate de polymyxine b 10000unité; bacitracine de zinc 500unité - antibiotics
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
lidodan jelly 2%(single use syringe)
odan laboratories ltd - chlorhydrate de lidocaïne - jelly - 2% - chlorhydrate de lidocaïne 2% - antipruritics and local anesthetics